Three induction programs burke

This clearly affirms the need for a well-structured and an equally well-executed corporate induction and onboarding training program to ensure that the new employees are not disenchanted. In fact, it should serve to enhance the positive image of the organization. The traditional face-to-face approach to render induction and onboarding programs is normally the approach most organizations opt for. This is of high impact, and the human touch goes a long way in helping new employees learn the organization culture, its value proposition, and how they can contribute very effectively.

However, this approach does have some challenges that can hamper the impact it aims to create. Increasingly, organizations are evaluating a transition to a blended or fully online approach to impart corporate induction and onboarding training. In this article, through a set of 7 examples, I show you how you can transform your existing corporate induction and onboarding training program to gain a higher impact through an online or a blended approach.

A well-designed corporate induction and onboarding training program provides the following benefits to the new employees:. From an organizational perspective, a well-designed corporate induction and onboarding training program provides the following benefits to the business:. The value of human interaction to learn the ropes cannot be over-emphasized. It is a great way to help new employees understand the new organization, its dynamics, and how they can align to the corporate goals and create their own success stories.

However, there are a few challenges associated with this approach that can impede the impact this approach aims to create. Specifically, the combination of online and face-to-face corporate induction and onboarding training program offers the following benefits to employees:. From an organizational perspective, fully online or blended corporate induction and onboarding training programs:.

These are highly customized to suit the requirements. Most of the corporate induction and onboarding training programs continue to be blended. Part 2: patients with a sufficient tumor shrinkage to be considered eligible for part 2 and they will be treated concomitantly with durvalumab and radiotherapy.

Part 3: patients with partial response or stable disease after part 2 will be eligible for durvalumab maintenance, for up to 2 years or until disease progression or unacceptable toxicity. Drug Information available for: Durvalumab. FDA Resources. Arms and Interventions.

Induction therapy: durvalumab plus histology-based chemotherapy regimen cisplatin or carboplatin plus vinorelbine for squamous histology and pemetrexed for non-squamous histology. Outcome Measures. Secondary Outcome Measures : Progression-Free Survival PFS of patients receiving durvalumab and chemotherapy induction followed by immuno-radiotherapy and durvalumab consolidation. OS is defined as the time from the date of start of induction treatment until death due to any cause.

Patients alive at the time of statistical analysis will be censored at their last information on vital status. The assessment of safety will be mainly based on adverse reactions ARs and the frequency and nature of SAEs. Toxicity and safety will be evaluated during each part of the program, throughout study duration.

Other Outcome Measures: Concordance between patients who reach the primary endpoint and patients who are included in part 2 after the evaluation of the multidisciplinary team [ Time Frame: Assessed up to 60 months ] To evaluate the concordance between patients who reach the primary endpoint and patients who are included in part 2 after the evaluation of the multidisciplinary team. Plasma for cfDNA will be analyzed through whole exome sequencing considering coding region only to assess correlation with response.

To assess the dynamic changes of the tumor mutational profile upon different treatment time points. Eligibility Criteria. This will not apply to patients with confirmed Gilbert's syndrome persistent or recurrent hyperbilirubinemia that is predominantly unconjugated in the absence of hemolysis or hepatic pathology , who will be allowed only in consultation with their physician.

Patient willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up. Whether the degree of tumor shrinkage will be sufficient to consider the patient eligible for part 2 will be discussed in a web multidisciplinary team among involved CCE centers. Any concurrent chemotherapy, immunotherapy, biologic, or hormonal therapy for cancer treatment.

Concurrent use of hormonal therapy for non-cancer-related conditions e. Major surgical procedure as defined by the Investigator within 28 days prior to the first dose of investigational product. History of allogenic organ transplantation. The following are exceptions to this criterion: Patients with vitiligo or alopecia Patients with Grave's disease not requiring systemic treatment within the past 2 years Patients with hypothyroidism e.

The following are exceptions to this criterion: Intranasal, inhaled, topical steroids, or local steroid injections e. Note: Patients, if enrolled, should not receive live vaccine whilst receiving IP and up to 30 days after the last dose of IP. Female patients who are pregnant or breastfeeding or male or female patients of reproductive potential who are not willing to employ effective birth control from screening to 90 days after the last dose of durvalumab monotherapy.

Known allergy or hypersensitivity to any of the study drugs or any of the study drug excipients. Judgment by the investigator that the patient is unsuitable to participate in the study and the patient is unlikely to comply with study procedures, restrictions and requirements.

Contacts and Locations. Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its ClinicalTrials.

More Information. Signatures of mutational processes in human cancer. Epub Aug Erratum in: Nature. Imielinsk, Marcin [corrected to Imielinski, Marcin]. N Engl J Med. Epub Sep 8. Epub Sep Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol. Epub Mar How can we optimise concurrent chemoradiotherapy for inoperable stage III non-small cell lung cancer?

Lung Cancer. Epub Dec 1. Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer. Cell Death Differ. Epub Jun Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer RTOG : a randomised, two-by-two factorial phase 3 study.

Lancet Oncol. Epub Jan Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. Epub Jun 2. J Clin Oncol ;32 Suppl. Brookmeyer R, Crowley J. A confidence interval for the median survival time. Biometrics , 38, Programmed death-1 ligand 1 interacts specifically with the B costimulatory molecule to inhibit T cell responses. Epub Jul Radiotherapy in combination with immune checkpoint inhibitors. Schedule a couple of experts to deliver lectures on different topics, spread over a number of days.

This will avoid cramming and overwhelming the new employees in a single day. Clearly put the expectations of your organization across to the new employees. This will help pave the way for what they need to be working towards right from day one.

For instance, if your company follows a policy for applying for leave in advance, make sure you explain the policy in clear and categorical terms. Encourage the employees to ask questions to clarify and answer them satisfactorily. An induction training is not the end of your face-to-face interaction with your new entrants.

Organize follow-up meetings a few weeks after the formal induction training. Find out how it is going, what challenges, if any, they are facing and offer to resolve them. Make yourself, the HR, and senior management fully accessible to your new employees. Nowadays, instructor-led classroom training is not enough; you have to reinforce with the latest training software for best results.

This is where induction training software steps in. The online induction training software can help accelerate induction training , save time, effort, and resources, and deliver positive outcomes through right learning opportunities. Such online induction software makes induction training manageable and effective, resulting in:. After you learn all the advantages of deploying induction training software and you are ready to give it a try, the next step in the process is knowing how to choose the right one.

This may seem a bit tricky to you initially, but once you understand what you need and what to look for in such a tool, everything becomes easy.

While the list of solutions any end user expects to see in online induction systems can be quite exhaustive, make sure the tool you choose provides you the following supports:. When it comes to delivering software products to customers, we at ProProfs believe in going out of our way to do it in the best possible way to ensure customer delight. Our flagship product, Training Maker, is a good example of it.

Try our online induction software for FREE. Induct new employees faster with ProProfs Training Maker. Happy onboarding! Michael has more than eight years of experience in the enterprise software and eLearning industry. He is passionate about online training and has a deep understanding of how organizations can leverage online training for maximum success.

In his free time, he enjoys power walking, zumba, and reading. We believe software should make you happy Learn more about us. May 31, Last modified: August 26,